新穎標靶青光眼藥物

An Novel ROCK Inhibitor for Glaucoma
青光眼是全球第二大的致盲因素,現行治療藥物易衍生藥效疲乏與副作用。ITRI-E-(S)4046是一種雙標靶作用激酶抑制劑,包含ROCK及Target X抑制作用,能降低眼壓並減少紅眼症,屬於全世界first-in-class的青光眼治療藥物。
Glaucoma is the second leading cause of global blindness, but the drugs for current treatments lead to decreasing drug effects and increasing side effects. ITRI-E-(S)4046 is a dual-target kinase inhibiter that inhibits ROCK and Target X to lower IOP and prevent pink eye. It is a global first-in-class drug for Glaucoma treatment.